Santoni N, Melo T, Aguirre AR, Veiga D, Souza C. Cost-effectiveness of afatinib versus pemetrexed plus cisplatin, erlotinib and gefitinib as first line treatment in patients with locally advanced or metastatic epidermal growth factor receptor mutation (EFGR+) non-small cell lung cancer in the Brazil. JBES [Internet]. 20º de abril de 2017 [citado 20º de setembro de 2025];9(1):73-82. Disponível em: https://www.jbes.com.br/index.php/jbes/article/view/295